Molecular analysis of metaplastic breast carcinoma: High EGFR copy number via aneusomy

Molecular Cancer Therapeutics

Volumn 7, Issue 4, 2008, Pages 944-951

  Gilbert, Judith A ^a   Goetz, Matthew P ^b   Reynolds, Carol A ^b   Ingle, James N ^b   Giordano, Karin F ^c   Suman, Vera J ^b   Blair, Hilary E ^b   Jenkins, Robert B ^b   Lingle, Wilma L ^b   Reinholz, Monica M ^b   Adjei, Alex A ^d   Ames, Matthew M ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Clinic   (United States)

^c EASTERN MAINE MEDICAL CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; IMATINIB; PROGESTERONE RECEPTOR; PROTEIN P63; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DNA ISOLATION; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE NUMBER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METAPLASIA; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; METAPLASIA; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS;

EID: 42249105872     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0570     Document Type: Article

References (33)

1. Rosen PP. Carcinoma with metaplasia. In: Rosen's breast pathology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 425-61.
2. Tavassoli FA. Classification of metaplastic carcinomas of the breast. Pathol Annu 1992;27 Pt 2:89-119.
3. Rayson D, Adjei AA, Suman VJ, et al. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol 1999;10:413-9.
4. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
6. Sotiriou C, Neo S-Y, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-8.
7. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
8. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.
9. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
10. Van de Rijn M, Perou CM, Tibshirani, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
11. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006;295:2492-502.
12. Koker MM, Kleer CG. p63 Expression in breast cancer. A highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004;28:1506-12.
13. Leibl S and Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 2005;58:700-4.
14. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21.
15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
16. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-50.
17. Reis-Filho JS, Pinheiro C, Lambros MBK, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006;209:445-53.
18. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55.
19. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a southwest oncology group study. J Clin Oncol 2005;23:6838-45.
20. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
21. Gilbert JA, Lloyd RV, Ames MM. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med 2005;353:209-10.
22. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002;77:148-54.
23. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur J Cancer 2006;42:17-23.
24. Cappuzzo F, Ligorio C, Janne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridizationpositive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007;25:2248-55.
25. Han S-W, Kim T-Y, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006;12:2538-44.
26. Shepherd FA, Tsao M-S. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006;24:1219-20.
27. Bhargava R, Gerald WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005;18:1027-33.
28. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7:R1028-35.
29. van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005;104:1781-8.
30. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-22.
31. Burger H, den Bakker MA, Kros JM, et al. Activating mutations in c-KIT and PDGFRα are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005;4:1270-4.
32. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor a tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23:49-57.
33. Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004;10:178-83.